122 related articles for article (PubMed ID: 18945509)
41. Pantalone et al.: the risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Bell DS
Acta Diabetol; 2009 Jun; 46(2):155; author reply 157. PubMed ID: 19300899
[No Abstract] [Full Text] [Related]
42. Comparison of diabetic control in type 2 (non-insulin dependent) diabetic patients treated with different sulphonylureas.
Harrower AD
Curr Med Res Opin; 1985; 9(10):676-80. PubMed ID: 3935376
[TBL] [Abstract][Full Text] [Related]
43. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
44. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR).
Gudbjörnsdottir S; Eeg-Olofsson K; Cederholm J; Zethelius B; Eliasson B; Nilsson PM;
Diabet Med; 2009 Jan; 26(1):53-60. PubMed ID: 19125761
[TBL] [Abstract][Full Text] [Related]
45. Metformin use in decompensated heart failure.
Boyd A; Nawarskas J
Cardiol Rev; 2008; 16(5):269-72. PubMed ID: 18708828
[TBL] [Abstract][Full Text] [Related]
46. Human paraoxonase gene polymorphisms and coronary artery disease risk.
Mendonça MI; Dos Reis RP; Freitas AI; Sousa AC; Pereira A; Faria P; Gomes S; Silva B; Santos N; Serrão M; Ornelas I; Freitas S; Araújo JJ; Brehm A; Cardoso AA
Rev Port Cardiol; 2008 Dec; 27(12):1539-55. PubMed ID: 19280995
[TBL] [Abstract][Full Text] [Related]
47. Factor V G1691A, prothrombin G20210A and methylenetetrahydrofolate reductase polymorphism C677T are not associated with coronary artery disease and type 2 diabetes mellitus in western Iran.
Rahimi Z; Nomani H; Mozafari H; Vaisi-Raygani A; Madani H; Malek-Khosravi S; Parsian A
Blood Coagul Fibrinolysis; 2009 Jun; 20(4):252-6. PubMed ID: 19349859
[TBL] [Abstract][Full Text] [Related]
48. Gene-gene interaction affects coronary artery disease risk.
Mendonça MI; Dos Reis RP; Freitas AI; Sousa AC; Pereira A; Faria P; Gomes S; Silva B; Santos N; Serrao M; Ornelas I; Freitas S; Freitas C; Araújo JJ; Brehm A; Cardoso AA
Rev Port Cardiol; 2009 Apr; 28(4):397-415. PubMed ID: 19634497
[TBL] [Abstract][Full Text] [Related]
49. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
50. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.
Mancini T; Mazziotti G; Doga M; Carpinteri R; Simetovic N; Vescovi PP; Giustina A
Bone; 2009 Oct; 45(4):784-8. PubMed ID: 19527806
[TBL] [Abstract][Full Text] [Related]
51. Sulfonylureas and the risk of myocardial infarction.
Thisted H; Johnsen SP; Rungby J
Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805
[TBL] [Abstract][Full Text] [Related]
52. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
[TBL] [Abstract][Full Text] [Related]
53. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
Stockl KM; Le L; Zhang S; Harada AS
Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
[TBL] [Abstract][Full Text] [Related]
54. Reverse modulation of the HDL anionic peptide factor and phospholipid transfer protein activity in coronary artery disease and type 2 diabetes mellitus.
Attia N; Domingo N; Lorec AM; Nakbi A; Hammami S; Ben Hamda K; Portugal H; Lairon D; Hammami M; Chanussot F
Clin Biochem; 2009 Jun; 42(9):845-51. PubMed ID: 19135989
[TBL] [Abstract][Full Text] [Related]
55. Prevalence of coronary risk factors in type 2 diabetics without manifestations of overt coronary heart disease.
Agarwal AK; Singla S; Singla S; Singla R; Lal A; Wardhan H; Yadav R
J Assoc Physicians India; 2009 Feb; 57():135-42. PubMed ID: 19582981
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of urolithiasis: a link between stone formation and diabetes mellitus?
Zimmerer T; Weiss C; Hammes HP; Braun C; Hesse A; Alken P; Knoll T
Urol Int; 2009; 82(3):350-5. PubMed ID: 19440027
[TBL] [Abstract][Full Text] [Related]
57. Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?
Nagendran J; Oudit GY; Bakal JA; Light PE; Dyck JR; McAlister FA
Diabetes Obes Metab; 2013 Nov; 15(11):1022-8. PubMed ID: 23668425
[TBL] [Abstract][Full Text] [Related]
58. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride.
Ebato C; Shimizu T; Arakawa M; Mita T; Fujitani Y; Watada H; Kawamori R; Hirose T
Diabetes Res Clin Pract; 2009 Oct; 86(1):31-6. PubMed ID: 19692134
[TBL] [Abstract][Full Text] [Related]
59. Level of high-sensitivity C-reactive protein in Saudi patients with chronic stable coronary artery disease.
Habib SS
J Ayub Med Coll Abbottabad; 2008; 20(2):3-6. PubMed ID: 19385446
[TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects.
Courtois P; Sener A; Herbaut C; Turc A; Malaisse WJ
Res Commun Mol Pathol Pharmacol; 1999 Feb; 103(2):211-22. PubMed ID: 10461687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
